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Abstract 
We show Protein Kinase C-zeta variant “b” (PKC-ζ-b) to be a novel predictive biomarker for survival 
from prostate cancer (p < 0.001). We also confirm that transcription of the PRKC-ζ gene is crucial to the 
malignant phenotype of human prostate cancer. Following siRNA silencing of PRKC-ζ in PC3-M 
prostate cancer cells, stable transfectant cell-line si-PRKC-ζ-b-PC3-MT1-6 is phenotypically non-
malignant in-vitro and in-vivo. Genome-wide expression analysis identified 373 genes to be 
differentially expressed in the knockdown cells and four key gene-networks to be significantly 
perturbed during phenotype modulation. Functional interconnection between some of the modulated 
genes is revealed, although these may be within different regulatory pathways, emphasizing the 
complexity of their mutual interdependence. Genes with altered expression following PRKC-ζ 
knockdown include HSPB1, RAD51 and ID1 that we have previously described to be critically 
important in prostatic malignancy. Since expression of PRKC-ζ-b is functionally involved in promoting 
the malignant phenotype, we propose PKC-ζ-b as a novel and biologically-relevant target for therapeutic 
intervention in prostate cancer.  
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Introduction 
Prostate cancer is the second most common cancer to affect men worldwide. In the USA, in 2008, 
186,320 new cases of prostate cancer and 28,660 deaths from this disease were reported 
1
. Equivalent 
figures from the United Kingdom reveal that in 2006, 35,515 new cases were diagnosed and that 10,239 
men died of this disease in 2007 
2
.  Unlike some human malignancies, prostate cancer is not associated 
with a specific high penetrance susceptibility gene 
3
 but with multiple gene loci 
4, 5
 each independently 
conferring a low but cumulative risk. The clinical potential of an individual prostate cancer may range 
from relative indolence to highly aggressive with progression occurring rapidly. Hence, there is an 
urgent requirement to develop reliable biomarkers that accurately stratify prostate cancer at diagnosis 
and segregate men with aggressive cancers requiring urgent treatment from those who may be managed 
conservatively 
6
. While extent of disease is more useful than clinical stage at diagnosis, and retains a 
low level of significance in multivariate analysis, neither parameters is of clinical utility being 
significantly inferior to Gleason score or PSA 
7
.  
 A potential functional relationship between PKC-ζ, encoded by the gene PRKCZ located on 
chromosome 1 at p36.33-p36.2, and prostate cancer was first suggested by our study that showed 
expression of PKC-ζ to be enhanced in prostatic malignancy when compared to morphologically non-
malignant prostatic epithelium 
8
.  These findings were subsequently validated by other studies in 
cancers of breast 
9
, lung 
10, 11
 and pancreas 
12, 13
. Reduction in PKC-ζ inhibits cell migration and 
invasion, confirming the protein to be functionally important to the malignant phenotype 
10, 11
. While 
our original data suggested that strong PKC-ζ expression might identify a subset of aggressive prostate 
cancers, the cohort was heterogeneous and too few to provide reliable statistics. This study has assessed 
PKC-ζ expression in the largest group of well-characterized and conservatively managed patients yet to 
be assembled world-wide 
7
. 
Protein Kinase C (PKC) isoenzymes together comprise a complex super-family of 14 serine-
threonine kinases characterized by structural similarities in certain gene-elements and functional peptide 
domains 
14
. Broadly considered as regulators of cellular homeostasis and behavioral phenotype, these 
enzymes are increasingly identified to be polyfunctional. The genes for all of these enzymes 
characteristically encode multiple splice variants that are differentially expressed between tissues in a 
wide range of animal species during tissue morphogenesis 
15
, especially between malignant tissues and 
their benign histogenic counterparts 
8, 12
. Different PKC isoforms exhibit opposing cell-regulatory 
actions 
16, 17
.  In prostate cancer, preliminary studies demonstrated only the expression of PRKC-ζ 
isoform “b” in PC3-M cells 18.  
 Examples of genes selectively modulated in prostate cancer are now relatively frequent 
19
. 
Some of these, either up- or down-regulated, have been proposed as robust biomarkers able to segregate 
different cancer phenotypes according to parameters that include behavior and response to therapy 
20
. 
While altered expression does not confirm, ipso facto, a functional role in malignancy, genes that we 
have demonstrated to be functionally relevant to the aggressive phenotype of prostate cancer include 
cFABP 
21
, RPL19 
22
, ID1 
23
, RAD51 
24
 and HSPB1 
25
. Studies reported from this laboratory 
26
 and 
elsewhere 
27, 28
 have also established a functional relationship between PKC-ζ voltage-gated ion 
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channels 
16
 and the invasive phenotype of prostate cancer cells 
29
. Similarly, the behavior of malignant 
cells is influenced by expression of cell-surface complex glycoconjugates, particularly sialic acids 
30, 31
. 
Therefore, the objectives of this study were: (i) to confirm the predictive biomarker potential of PKC-ζ-b 
protein expression in a large cohort of untreated human prostate cancers (ii) to test the hypothesis that 
translation and expression of PRKC-ζ is functionally important in promoting and/or maintaining the 
aggressive phenotype of prostate cancer, and hence a potential drug target, and (iii) to elucidate the 
genes and their associated networks modulated by PRKC-ζ.  
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Results 
PKC-ζ protein expression in prostate tissues and clinical correlations 
Information on PKC-ζ staining intensity was available for 2879 cores from 783 patients. Morphological 
appearances of the distribution of cytoplasmic PKC-ζ expression ranged from benign through malignant 
(Figure 1). For the 667 patients with positive staining (i.e. ≥ 1), their demographics and tumor 
characteristics are presented in Table 1. Figures 2a & 2b show the distribution of PKC-ζ staining and 
intensity in the 901 morphologically unremarkable cores (10%), 798 hyperplasic cores (36%), 38 PIN 
cores (76%) and 1142 cancer cores (90%) analyzed in the arrays. The relationship of PKC-ζ expression 
(binary variables: staining intensity ≤ 2 and = 3) with demographics and tumor characteristics is 
presented in Table 2.  At both levels, PKC-ζ expression was associated with Gleason score (p < 0.001), 
clinical stage (p < 0.001) and amount of cancer in each specimen (p < 0.001). No association was found 
with age or baseline PSA. At high intensity (i.e. = 3+), expression of PKC-ζ was associated with worse 
survival from prostate cancer (Figure 2c) and poor overall survival (Figure 2d). Univariate Cox model 
analysis (Table 2) revealed PKC-ζ expression to be a significant prognostic factor of cause-specific 
survival (
2 
= 20.53, p < 0.001) and overall survival (
2
=8.54, p = 0.002). However, when added to a 
model with Gleason score, PKC-ζ expression became a weakly significant prognostic factor for cause-
specific survival (HR = 1.44, 95% CI = 1.00-2.07, p = 0.05). Similarly, when added to a multivariate 
model comprising Gleason score, extent of disease, baseline PSA and age at diagnosis, PKC-ζ 
expression was of borderline significance (HR = 1.41, 95% CI = 0.98-2.02, p = 0.06) In each 
multivariate of these models, there was no association with overall survival. We conclude from these 
analyses that PKC-ζ expression is highly correlated with existing prognostic markers including Gleason 
score and clinical stage but does not, alone, represent an independent prognostic marker. However, 
within poor-prognosis prostate cancers, it might define a phenotypic subset amenable to therapeutic 
manipulation of PRKC-ζ-b. 
 
PRKC-ζ-b mRNA expression 
Previous Western blotting studies indicated that PRKC-ζ-b was the only isoform expressed in prostate 
cancer cell-lines and most strongly expressed in PC3-M cells (Figure 3a) that we selected for use as our 
model system. qRT-PCR (Figure 3b) revealed PRKC-ζ-b mRNA expression in PC3-M (androgen-
independent) cells at ~5-fold (p < 0.01), DU145 at ~5-fold (p < 0.01) and LNCaP  (androgen-
dependent) at ~3-fold (p < 0.01) higher than that in PNT-2 cells (Figure 3c). We used PRKC-ζ-b siRNA 
expressed in pSilencer™ 4.1-CMVneo (Ambion) to create nine PC3-M transfectant cloned cell-lines 
(si-PRKC-ζ-b-PC3-MT1-1 - T1-6 and si-PRKC-ζ-b-PC3-MT2-1 - T2-3). All nine clones displayed a significant 
loss of substrate adhesion when compared to un-transfected PC3-Mcontrol cells. The transfected cells 
appeared disparate, non-adhesive and contained multinucleate forms easily identifiable microscopically 
(Figure 3d), suggesting failure to complete mitosis. mRNA analysis (Figure 3e) demonstrated the most 
consistent effective reduction in colony si-PRKC-ζ-b-PC3-MT1-6, in which PRKC-ζ-b was reduced to 37% 
± 17% of the PC3-Mcontrol cells relative to β-actin (p < 0.005). Other cell lines exhibited less reduction, 
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ranging from 43% ± 4% to 54% ± 8% (p < 0.01) or were less consistent in their level of gene 
knockdown. Cells transfected with empty vector and PC3-Mscramble cells exhibited no significant 
reduction in their level of PRKC-ζ-b mRNA (p > 0.5).  
 
Growth characteristics of si-PRKC-ζ-b-PC3-MT1-6 cells in-vitro 
Proliferation assay revealed the rate of cell division by the si-PRKC-ζ-b-PC3-MT1-6 cells was 
significantly reduced (p < 0.05) when compared to PC3-Mcontrol and PC3-Mscramble (Figure 4a). Apoptosis 
quantified by flow cytometry, was not significantly affected in the transfected si-PRKC-ζ-b-PC3-MT1-6 
cells (Figure 4b). The levels of endogenous apoptosis identified within the control cells were similar to 
those obtained during comparable studies of the RPL19 gene 
32
. In the soft agar tumorigenesis assays 
(Figure 4c), cell colonies formed after three weeks. PNT-2 cells yielded no colonies while PC3-Mcontrol 
cells and all transfectant cells formed colonies (Figure 4d). Whereas parental PC3-Mcontrol cells 
generated 499 ± 22 colonies and PC3-Mscramble cells generated 541 ± 10 colonies, the si-PRKC-ζ-b-PC3-
MT1-6 cells generated 120 ± 11 colonies (p < 0.005). In the Matrigel invasion assay, all knockdown cell-
lines revealed reduced cell migration (p < 0.01) when compared to the parental PC3-Mcontrol cells, (1775 
± 65 cells). The si-PRKC-ζ-b-PC3-MT1-1 cells scored 106 ± 26 cells migrating while si-PRKC-ζ-b-PC3-
MT1-2 cells scored 129 ± 26 cells (Figure 4e,f). Thus, the effect of selectively inhibiting PRKC-ζ-b was to 
severely reduce the ability of all transfected cells to invade a semi-solid collagen-based stroma. 
 
Tumorigenic behavior of si-PRKC-ζ-b-PC3-MT1-6 cells in-vivo 
Statistically significant reductions in tumor volume and weight occurred for PRKC-ζ-b-PC3-MT1-6 cells. 
Comparison of mean tumor volumes (Figure 5a) revealed: PC3-Mcontrol (272 ± 213 mm
3
), PC3-Mscramble 
(81 ± 70 mm
3
), si-PRKC-ζ-b-PC3-MT1-2 (9 ± 8 mm
3
) and si-PRKC-ζ-b-PC3-MT1-6 (36 ± 38 mm
3
). 
Significant differences were observed between the PC3-Mscramble group and si-PRKC-ζ-b-PC3-MT1-6 (p < 
0.005, Mann-Witney U Test). At autopsy (Figure 5b), the average tumor weight generated by PC3-
Mcontrol cells (337 ± 249 mg) was 4.7-fold and 21-fold, respectively, higher than that of the siRNA 
transfectant cells si-PRKC-ζ-b-PC3-MT1-2 (16 ± 11 mg) and si-PRKC-ζ-b-PC3-MT1-6 (71 ± 80 mg). The 
mean tumor weight generated by PC3-Mscramble cells was 7.5 fold higher than that in the group si-PRKC-
ζ-b-PC3-MT1-2 (p < 0.005) and in si-PRKC-ζ-b-PC3-MT1-6, although no significant was observed between 
PC3-Mscramble and si-PRKC-ζ-b-PC3-MT1-6. However, the trend in tumor weight between the control 
groups and the transfectant gene knockdown groups decreased dramatically (Figure 5c). Although the 
mean weight of the si-PRKC-ζ-b-PC3-MT1-6 tumors was higher than that in the si-PRKC-ζ-b-PC3-MT1-2 
group, the difference was not significant. 
 
Hsp-27 expression and phosphorylation status 
PKC-ζ and Hsp-27 are known to be involved in the regulation of cell locomotion and metastasis, 
particularly through actin filament organization 
25
, although no direct relationship has been reported 
between these two proteins. Western blotting confirmed the level of Hsp-27 expression identified by the 
generic antibody to be lower in the PNT-2control cells than in the PC3-Mcontrol, PC3-Mscramble and the si-
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PRKC-ζ-b-PC3-MT1-6 lines, where expression was comparable (Figure 6a). While no differences were 
apparent in the site-specific phosphorylation of PC3-Mcontrol and PC3-Mscramble, phosphorylation of Ser
82
 
was significantly enhanced in the si-PRKC-ζ-b-PC3-MT1-6 cells. Phosphorylation at Ser
15
 and Ser
78
 was 
similarly low in PC3-Mcontrol and PC3-Mscramble when compared to the benign PNT-2controls. Thus, unlike 
the effect of knocking-down the genes FABP5 or RPL19, reducing PRKC-ζ-b expression did not alter 
the overall level of Hsp-27 protein but selectively increased Hsp-27 phosphorylation at Ser
82
 although 
not at Ser
15
 or Ser
78
.  
 
Glycoconjugate expression 
Western blotting to detect sialylated glycoproteins revealed subtle differences in binding-patterns 
between the control and knockdown cells, particularly gain of Neu5Acα2,6Gal- structures identified by 
Sambuccus (Figure 6b) indicating significant changes to specific proteins. These might be caused by 
modulated levels of the particular proteins or changes in the structure of their oligosaccharides 
consequent upon alterations to the level of certain glycosyltransferases. Intact PC3-Mcontrol and si-
PRKC-ζ-b-PC3-MT1-6 cells expressed identical patterns of complex oligosaccharides identified by the 
five lectins (Table 3). The expression of sialic acids linked either Neu5Acα2,6Gal- (Sambuccus) or 
Neu5Acα2,3Gal- (Maackia) was confirmed following neuraminidase digestion of the intact cell 
preparations but revealed no gross differences (Figure 6c). The biotinylated lectins from Ulex 
europaeus, Lotus tetragonolobus and Aleuria aurantia were employed to detect subtle differences in 
terminal fucosyl linkages recognized to modulate metastatic behavior of a range of malignancies 
especially prostate cancer cell trafficking 
33
.  No differences were revealed in terminal fucose linked L-
Fucα1,6GlcNAc-/L-Fucα1,2Glc- (Lotus) or L-Fucα1,6GlcNAc-/L-Fucα1,3NLac- (Aleuria) although L-
Fucα1,2Galβ1- (Ulex) was not identified in either the control or knockdown cells. 
 
Comparative DNA oligonucleotide expression profiling of si-PRKC-ζ-b-PC3-MT1-6 cells 
No statistically significant (adjusted p ≥ 0.05) differences were found between PC3-Mcontrol and PC3-
Mscramble cell-lines, confirming that the transfection technique was not responsible for off-target effects 
to bias the experimental data. The hybridisation data revealed 549 DNA sequences representing 373 
genes to be differentially expressed (p ≤ 0.05, Benjamini and Hochberg multiple testing correction 
applied) following RNAi knockdown of PRKC-ζ-b. Of these, 85 genes were enhanced and 288 down-
regulated, 188 different genes being modulated at least four-fold, 31 up-regulated (Supplemental Table 
1) and 157 down-regulated (Supplemental Table 2). Frequently, multiple sequences for an individual 
gene were ranked in close proximity, confirming the quality of this dataset. For three up-regulated 
genes (PLAT, CDKN2C and HSPB1) and one down-regulated gene (FOXA2) the alterations were 
validated in qRT-PCR experiments (data not shown). According to current databases (Gene Cards 
http://www.genecards.org/ and AceView NCBI http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/) 
these genes reflected a wide range of biological functions, with Gene ontology (GO) term enrichment 
analysis identifying some 40 biological process and 13 molecular function GO terms (Supplemental 
Tables 3,4) to be significantly associated (p < 0.001) different. A heat map generated from the 100 
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genes most affected (Figure 7) showed the knockdown phenotype to be distinct and further shifted from 
the parental PC3-M cells than the non-malignant PNT-2 cells, thus confirming modulation of the 
malignant phenotype through down-regulation of PRKCZ-ζ-b.  Ingenuity pathway analysis identified the 
top four ranked interlinked pathways and biological networks (Supplemental Table 5) containing genes 
expressed differentially following PRKC-ζ knockdown to be highly significant (p ≤ 10-28) and to include 
two networks with genes regulated by NFκB, networks centralised around p53 and networks around 
KDMSB, MCM6 and DDIT3 (Figure 8). This analysis further revealed that some of the genes modulated 
by down-regulated expression of PRKC-ζ-b are not discrete or independent but are functionally 
interconnected. This high level of cross-talk between apparently different biological processes provides 
the possibility for strategic manipulation of a single gene (demonstrated by the modulation of PRKCZ-ζ-
b) to profoundly affect the phenotype of target cancer cells. 
 
Glycosyltransferase genes modulated in si-PRKC-ζ-b-PC3-MT1-6 cells 
Interrogation of the gene expression array data confirmed down-regulation of glycosyltransferase 
enzyme genes GALNTL4 (~1.5-fold p < 0.01) and GCNT3 (~1.5-fold p < 0.01). Potentially, their 
change in expression would significantly alter the terminal antennary structure of glycoprotein 
oligosaccharides thus affecting the substrates available for subsequent fucosyl- and sialyl-transferase 
activity 
34
.  This possible mechanism is supported by the elevated expression (~1.6-fold p < 0.01) of the 
sialyl-transferase gene ST6GALNAC2 (N-acetyl-GalNAc2,6sialyltransferase) responsible for the 
Neu5Acα2,6Gal- structure identified by Sambuccus and found to be increased in the PRKCZ-ζ-b 
knockdown cells (Figure 6b).    
 
Ion channel genes modulated in si-PRKC-ζ-b-PC3-MT1-6 cells 
The oligonucleotide expression arrays were interrogated to determine whether genes encoding ion 
channels were modulated following PRKC-ζ-b knockdown. Two groups affected were voltage-gated K
+
 
channel genes KCNN4 (up-regulated ~2.4-fold, p < 0.005), KCNK10 (down-regulated ~1.8-fold, p < 
0.01) and KCNMA1 (down-regulated ~1.5-fold, p < 0.01) together with the Na
+
/K
+
 transporting 
ATPase’s β1and β3 polypeptide genes ATP1B1 (down-regulated ~1.6-fold, p < 0.01) and ATP1B3 
(down-regulated ~1.5-fold, p < 0.01). Although the specific functions of these channels is complex, 
they are all involved in cellular homeostasis of various types, including maintenance of cell polarity. 
These expression array data reveal a possible functional interaction between the glycosyltransferase 
genes and the ion channel genes such that they together contribute to modulating the parental PC3-M 
cells from a malignant towards a benign phenotype. 
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Discussion 
At diagnosis, PKC-ζ protein expression is confirmed as a powerful predictive biomarker for survival 
from prostate cancer (p < 0.001) and for overall survival (p < 0.001). Furthermore, PKC-ζ expression 
accurately segregates men with poor prognosis prostate cancer that requires active treatment from those 
with relatively indolent disease that should be managed conservatively. PKC-ζ expression also 
correlates strongly with Gleason grade (p = 0.001) but not with baseline PSA values (p > 0.2) despite 
PSA being an independent predictive variable in the original cohort of patients 
7
.  In multivariate 
analysis, diminished significance (p < 0.05) of this variable suggests that it defines a biologically 
distinct group within the overall population of aggressive prostate cancers. Although most benign 
tissues did not express PKC-ζ, a small proportion of hyperplasias and PIN (Figure 2a,b) were stained, 
indicating that early up-regulation of the protein may be a biomarker of epithelial pre-neoplasia in-situ, 
one of the precursors of invasive prostate cancer 
35
. 
These RNAi studies, the first to be reported in human prostate cancer (Supplemental Table 6), 
support the original hypothesis by establishing functionality of PRKC-ζ-b in the malignant phenotype of 
human prostate cancer cells. Knockdown of the gene results in a significant reduction in malignancy, 
confirmed both in-vitro and in-vivo. The subsequent array data also show that PRKC-ζ-b is pleiotropic 
and regulates a variety of genes involved in several distinct but interactive networks. Hence, there is no 
single mechanism by which PRKC-ζ-b knock-down ameliorates the malignant phenotype. Nevertheless, 
one of the critical mechanisms revealed by this study is consistent with modulation of the genes for ion 
channels KCNK10 and KCNMA1. Cellular proliferation of prostate cancer cells is controlled by a 
variety of K
+
 channels, including voltage-, Ca
2+
-, ATP-gated and two-pore K
+
 and maxi-KCa channels 
36
 
encoded by KCNK10 and KCNMA1 through in a regulatory network with PRKC-ζ-b. Conversely, down-
regulation of voltage-gated K
+
 channel activity can be associated with invasive behavior 
36
. Such 
behavior could be subserved by KCNN4 coding for small/intermediate-conductance KCa channels found 
earlier in the metastatic PC-3 but not in non-metastatic LNCaP cells 
37
. These data together with the 
finding that enhanced KCNMA1 expression is functionally involved in breast cancer invasion and 
metastasis to brain 
38
, not only exemplify the biological relevance of these channels but supports a 
reciprocal interaction between ion channels, alterations in glycosyltransferase expression and 
malignancy. The cellular distribution and role of the ion channels modulated following PRKC-ζ-b- 
knockdown is directly dependent upon their appropriate patterns of N-linked glycosylation such that 
any alteration inhibits their functionality causing impaired cell polarization 
39, 40
.  Similarly, changes in 
ion channels disturb intracellular pH gradients with the consequence that certain proteins undergo 
alternative patterns of glycosylation, as evidenced by the glycoconjugate expression data (Figure 6) 
potentially resulting in their modulated distribution and/or functionality 
41
.   
The importance of PRKC-ζ-b in prostate cancer cell motility is supported by reduced colony 
formation in soft agar and impaired tumor cell invasion through a collagen matrix (Figure 4c-f) 
following gene knock-down. A similar role for PKC-ζ has been proposed in pancreatic cancer cells 13 
after inhibition of PRKC-ζ either chemically 42 or genetically 43. To develop the mechanical forces 
necessary for cell migration, as well as interacting with actin 
44, 45
, direct phosphorylation of myosin II-
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B protein by PKC-ζ occurs in TSU-pr1 prostatic adenocarcinoma cells in an EGF-dependant manner 
when complexed with p21-activated kinase-1 (PAK-1). In this pathway, PKC-ζ is phosphorylated and 
activated by PAK-1, promoting phosphorylation of myosin II-B 
46
.  
In addition to a functionally-competent locomotor assembly, maintenance of cell polarity and 
loss of cell-cell adhesion are essential for cell migration 
47
. For a cell to migrate, generation of a 
forward-rear polarity axis occurs principally through the PAR-PKC-ζ system 48.  A complex established 
between PAR6-Akt2 and PKC-ζ is activated by Cdc42 49. Upstream, the interaction between PKC-ζ and 
Akt2 is regulated directly by EGF 
50
 and indirectly by TGFbeta controlling the integrity of intracellular 
tight junctions through the interaction of PAR6 with TGFbeta receptors 
51
. During locomotion, 
stabilization of lamellipodia required for cell migration and invasion 
52
 involves formation of the 
Cdc42/PAR6/Akt2/Rac1 polarity complex that, following activation by PKC-ζ, recruits Smurf1 to 
regulate the local level of RhoA 
45
. Within these lamellipodia, phosphorylation of Hsp-27 
simultaneously modulates transformation of G→F actin 53 in the presence of fascin to generate the 
mechanical forces required for cell motility to occur through organization of cytoskeletal components 
54
 
that we have previously shown to characterize the aggressive phenotype of human prostate cancer 
25
. 
Our current studies clearly demonstrate enhanced site-specific phosphorylation of Hsp-27 Ser
82
 in si-
PRKC-ζ-b-PC3-MT1-6 cells when PKC-ζ-b is reduced (Figure 6a). Thus, human prostate cancer cells 
depend upon the presence and integrity of both PKC-ζ-b and Hsp-27 to develop a malignant phenotype 
that is biologically competent to invade and metastasize. Presently, these are regarded as simultaneous 
and independent processes because there is no evidence of that Hsp-27 Ser
82
 is a substrate for PKC-ζ-b 
phosphorylation or that PRKC-ζ-b transactively regulates transcription of HSPB1 and hence the level of 
Hsp-27, despite increasing evidence that PKC-ζ is an essential transcriptional regulator for other genes 
10, 55, 56
.  
 Identification of gene interaction networks is a powerful approach to segregating prostatic 
malignancies into biologically-defined groups amenable to different types of therapeutic intervention 
57, 
58
.  However, there is a caveat that application of the types of data reported herein depends upon the 
integrity and expression of key genes that determine the genotype of each individual prostatic 
malignancy. In PC3-M prostate cancer cells, the gene TP53 is non-mutated, characteristic of 
approximately 60% of primary prostate cancers, supporting the proposition that down-regulation of 
PRKC-ζ would be effective in this group. Such cells are potentially able to regulate DNA replication 
through GINS complex members 
59
, an essential component of the human replisome. In the current 
study, down-regulation of GINS2 (~7-fold, p < 0.05) was associated with a concomitant reduction in 
PCNA (~8-fold, p < 0.01), CDC2 (~7-fold, p < 0.05), CCDC74B (~8-fold, p < 0.01) and CDC45L (~10-
fold, p < 0.05) indicating altered regulation of mitosis during initiation as well as S-phase and G2-M 
progression 
60
 to occur as a consequence of PRKC-ζ-b knockdown. This method has revealed the 
members of several different networks to be reduced following knockdown of PRKC-ζ-b (Supplemental 
Table 2). These included the gene ID1 (~8-fold, p < 0.05) and RAD51 (~10-fold, p < 0.01) that we have 
already shown to be associated (p < 0.001) with aggressive prostate cancer 
23, 24
. In this study, members 
of the NFκB pathway were principally reduced, particularly NFKBIA (~10-fold, p < 0.01).  The NFκB 
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complex is recognized to be inhibited by IκB proteins (NFκBIA or NFκBIB) that trap and inactivate 
NFκB 61.  Phosphorylation of serine residues within the IκB proteins by a range of kinases marks them 
for destruction following ubiquitination, thereby allowing activation of the NFκB complex.  
Simultaneous up-regulation of phosphoenolpyruvate carboxykinase 2 (PKC2, ~4-fold, p < 0.05, 
Supplemental Table 1) provides evidence of a more complex pathway modulated by PRKC-ζ-b 
knockdown. Other genes down-regulated in this extensive network include BEX1 (~15-fold, p < 0.05), 
CLX1 (~70-fold, p < 0.01) and CLX2 (~20-fold, p < 0.05). BEX1 knockdown accelerates cell 
differentiation and potentiates NFκB in response to NGF while reduction of CXCL1 and CXCL2 
expression is NFκB-dependent, requiring intact IκB. 
 This study has revealed how suppression of a single key pleiotropic gene in an established 
cancer cell can perturb the interactive balance between members of the cell’s genome so that a shift 
occurs from a malignant to a benign phenotype. Interpolation of the current data suggests that such an 
effect may be the converse of the network imbalance now believed to be generated by the combined 
small effects of a number of different genes acting together to promote emergence of the malignant 
phenotype 
3, 62
.  Although RNAi is effective in-vivo against established prostate cancers 
63
, small 
molecule inhibitors would provide a more flexible therapeutic approach. Novel protein kinase C 
inhibitors 
64
, already exhibit both tissue- and tumor-specificity against different PKC isoforms 
65
.  
Presently, the most effective agents are the PKC-β inhibitors briostatin-1 and enzastaurin, the latter 
being trialed against human lung cancer 
66
 while in human NSCLC, aurothiomalate and aurothioglucose 
are selective and effective inhibitors of PKC-ι, the homologue of PKC-ζ 67. Recently, spheciosterol 
sulfates extracted from Philippine sponges 
68
 and a novel class of small molecules (the 3-hydroxy-2-(3-
hydroxyphenyl)-4H-1-benzopyran-4-ones) have been described as isoform-selective PKC-ζ inhibitors 
69
.  Therapeutically employed for psychostimulant abuse, the potential value of these latter agents has 
yet to be assessed in treating epithelial malignancies. With reference to their inhibitory effects on 
prostate cancer metastases, bisphosphonates (e.g. pamidronate) specifically inhibit PKC-α and PKC-ζ, 
possibly through a network effect on urokinase-type plasminogen activator 
70
.  It is anticipated that the 
emerging PKC isoform-selectivity of new small molecule inhibitors 
71
 together with the identification 
of tissue-specific PKC variants 
18, 72
 will provide a high level of tumor-specificity for therapeutic 
intervention in the management of malignant diseases. 
Herein, we provide robust evidence that PKC-ζ- is not only functionally involved in promoting 
and maintaining prostate cancer but that the gene PRKC-ζ-b is a biologically effective target for control 
of this malignancy. Furthermore, the consequences of reducing PKC-ζ through PRKC-ζ-b gene 
knockdown, particularly identification of other potential targets such as the voltage-gated K
+
 channels 
73
, allows development of a comprehensive therapeutic strategy based upon detailed knowledge of 
biological pathways active in subsets of human prostate cancer. Understanding the potential impact of 
such approaches is not possible without a robust and validated database of molecular interactions. For 
cancer therapeutics, there are two corollaries: First, is that mathematical modeling of genes expressed 
by an individual cancer will allow accurate prediction of susceptibilities and weaknesses that might be 
exploited to treat each malignant disease in a biologically-appropriate manner 
74
.  Second, is the concept 
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of phenotypic modulation to treat cancers 
75
.  Through phenotypic modulation, prevention of metastases 
while maintaining the general health of a patient with early cancer would provide additional time to 
introduce second-line therapies to target specific networks such as NFκB 76, 77 in the knowledge that 
these would be biologically appropriate to accommodate the phenotypic changes induced in malignant 
cells by a first-line therapy. 
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Materials and Methods 
Patient Cohort and Tissue Micro-Arrays (TMAs) for PKC-ζ analysis 
The study analysed a panel of TMAs constructed from a retrospective cohort of  >2000 men with 
prostate cancer assembled from the records held by UK cancer registries and managed only 
conservatively 
7, 78
.  
 
Ethical approval 
National approval for the collection of the cohort was obtained from the Northern Multi-Research 
Ethics Committee followed by local ethics committee approval at each of the collaborating hospital 
trusts. This work was approved by the Clinical Research and Ethics Committee at the Royal Marsden 
Hospital and The Institute of Cancer Research.  
 
PKC-ζ immunohistochemistry 
Mouse monoclonal antibody sc-216 to PKC-ζ (Insight Biotechnology Ltd. Wembley, Middlesex, UK) 
recognizes a unique 20-peptide sequence located in the –COOH terminal domain of variant “b” 
(NM_002774) encoded by exon 90 (AceView nomenclature) of the PRKCZ gene 18. TMA sections 
were processed, stained and analyzed 
8, 25
. 
 
Analysis of PKC-ζ expression 
Specimens were considered positive only when at least 5% of the epithelial cells (either normal or 
malignant) unequivocally expressed PKC-ζ staining 79.  This cut-off was the same as that used to 
distinguish positive and negative immunohistochemical staining in our previous studies 
8, 25
.  Staining 
was assessed as negative, weakly positive or only focally positive (low-level expression), or strongly 
positive (high-level expression) and scored as 0, 1, 2 or 3, respectively.  
 
Statistical analysis of TMA immunohistochemistry 
The primary endpoint for this study was time to death from prostate cancer. Time to death from 
any cause was the secondary endpoint. Univariate and multivariate analysis were performed by 
proportional hazard (Cox) regression analysis 
25, 80
. Correlation of PKC-ζ staining (3+ vs 2+ or 
less) with other known prognostic factors was done by 2-sample trend tests.  
 
Cell lines 
Human prostate cell-lines PNT-2 (benign) and PC3-Mcontrol (highly malignant) were grown as 
monolayer cultures in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 10% (v/v) foetal calf 
serum (FCS, Invitrogen), penicillin (1000units/ml), streptomycin (100μg/ml), and L-glutamine (2mM). 
Media for the culture of all subsequent transfected cell-lines were also supplemented with 1µg/µl 
Geneticin (Sigma).  
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RNAi molecule designed to knock down PRKC-ζ-b 
A unique 21nt sequence (GTGAGAGACATGTGTCGTCTT) located at the 5’ end of PRKC-ζ-b was 
selected as the target site beginning with AA dinucleotide downstream of the start codon according to 
the siRNA user guide (http://www.rockefeller.edu/labheads/tuschl/project.html) using siRNA Target 
Finder http://www.ambion.com/techlib/misc/siRNA_finder.html.  The target site was a unique sequence 
within an exonic coding region of the human PRKCZ gene and not recognized elsewhere in the human 
genome. Of the 40 potential PRKCZ splice variants, BLAST search against NCBI Human Nucleotides 
Database, GenBank, RefSeq and PDB confirmed this sequence to be contained within PRKCZ variants 
“a”, “h”, “l”, “v-l” and “v-f” in addition to variant “b”, the wild-type variant (NM_002774) recognized 
to occur in human prostate cancer. These are either not expressed in prostatic carcinoma cells PC3-M, 
Du145 or LNCaP or are truncated and considered to be functionally ineffective.  
 
Top Strand:  
5'-GATCCGTGAGAGACATGTGTCGTCTTCAAGAGAGACGACACATGTCTCTCACTTA-3' 
Bottom Strand: 
5’-CTAGGCACTCTCTGTACACATCAGAAGTTCTCTCTGCTGTGTACAGAGAGTGAAT -3'  
 
The default Ambion loop sequence, TTCAAGAGA, was used to complete the hairpin structure. The 
siRNA expression vector kit used was pSilencer™ 4.1-CMV neo (Ambion). Top and bottom strands of 
the siRNA hairpin oligonucleotide were diluted to 1µg/µl in TE buffer and annealed in 50µl solution 
according to the manufacturer’s instructions. The annealed siRNA template was ligated into the 
pSilencer 4.1-CMV vector using T4 DNA ligase (5U/µl) and the products cloned into DH5α cells 
(Invitrogen). Transformed cells were grown for 16 hours on LB plates containing 100µg/ml ampicillin at 
37⁰C. A negative control of non-transformed competent cells was also included. Clones were picked and 
the DNA plasmid isolated using a Qiaprep spin Miniprep Kit (Qiagen, Crawley, UK). Isolated plasmids 
were digested with BamHI and HindIII (New England Biolabs, Hitchin, UK) and the presence of the 
siRNA 55bp insert was confirmed by sequencing prior to the siRNA expression vector being used to 
transfect recipient prostate cancer cell-lines. Orientation of the insert was confirmed by DNA 
sequencing (Lark Technologies, Essex, UK) using internal sequence primers. 
 
Transfection of siRNA PRKC-ζ-b silencing construct 
1.5x10
5
 PC3-M cells were transfected with pSilencer 4.1 CMV PRKC-ζ-b siRNA (1μg) or pSilencer 4.1 
CMV-scramble-insert (1μg) using SiPORT XP-1 (3μl) reagent (Ambion, Warrington, UK) in 6-well-
plates (35mm diameter). 24 hours after transfection, 500ng/ml of G418 was added to medium 
RPMI1640 for selection. After 9-10 days selection, individual colonies from single cells containing 
stable clones were isolated using ring cloning and transferred into 24-well plates with medium 
containing G418 at 500ng /ml. 
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RNA extraction and cDNA synthesis 
Total RNA was extracted with RNeasy Mini Kits (Qiagen). Total RNA concentration was measured 
using a NanoDrop (Labtech, Ringmer, UK) and RNA integrity assessed with a 2100 Bioanalyser 
(Agilent, Santa Clare, USA). The RNA integrity number (RIN) for all RNA used exceeded 9.0. First 
strand cDNA was synthesized from 0.5µg total RNA using AffinityScript™ Multiple Temperature 
cDNA synthesis kits (Stratagene, La Jolla, USA) according to the manufacturer’s protocol. 
 
Quantitative Real-Time PCR (qPCR) 
PRKC-ζ-b mRNA expression levels were quantified by qPCR and normalized relative to human β-actin 
mRNA expression. Primer sequences employed are shown in Table 4. Reaction volumes were in 25 µl 
comprising 12.5 µl Stratagene's Brilliant® SYBR® Green Master Mix (2X), 0.5µM of both forward 
and reverse primers, 1µl cDNA and 11.5 µl water. Primers for qPCR were designed to span exon/exon 
boundaries within the mRNA to avoid amplification of genomic DNA.  
 
Proliferation assay of controls and siRNA transfectants 
An assay to identify the effect of PRKC-ζ-b suppression on cellular proliferation assessed cell-lines 
PNT-2, PC3-Mcontrol, PC3-Mscramble and two si-PRKC-ζ-b-PC3-M clones. Exponentially-growing cells 
were seeded in triplicate sets at a density of 1 x 10
3 
cells/ml/well in 24 well plates. Over 6 days at 24 
hour intervals, cell proliferation was calculated by measuring the increase in cell numbers in each 
replicate using a conventional MTT assay 
81
.  
 
Apoptotic properties of controls and siRNA transfectants 
Apoptosis was quantified using flow cytometry. Cells were seeded at 2x10
5
 cells/ml in 75cm
2
 tissue 
culture flasks and the assay conducted during their linear growth-phase prior to reaching confluence. 
Cells were harvested by trypsinization, washed twice with PBS and re-suspended in buffer from the 
BioVision Annexin V-FITC kit in a 5ml flow cytometry tube. AnnexinV-FITC (5µl) and propidium 
iodide (10ng in 5µl aqueous solution) were added and the tubes incubated for 10 minutes in darkness at 
4°C. Quantitative analyses of apoptotic cell levels were performed using an Epics Flow Cytometer 
(Beckman Coulter). The procedure was performed three times using biological replicates. 
 
Soft agar tumorgenicity assay 
Cells were grown under standard environmental conditions as suspension cultures at a concentration of 
2.5 x 10
3
 cells/ml in 0.3% (w/v) agarose at 37ºC, 100% humidity and 5% CO2 in air. After 3 weeks 
incubation, cell colonies were counted and photographed using a GelCount™ (Oxford Optronix, 
Oxford, UK) instrument. Any colonies of diameter <30µm or >100µm were excluded, the latter 
probably signifying that these were not derived from single cells. 
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In-vitro invasion 
Invasiveness of the si-PRKC-ζ-b transfectants was assessed in-vitro 
82
.  At 24-hour intervals, following 
fixation and staining with Crystal Violet (Sigma-Aldrich, St Louis, USA), invasion was measured by 
counting the number of cells transmigrating the membrane to its under-surface. 
 
In-vivo growth 
Tumorigenicity and metastatic ability in-vivo were measured 
83
. A deposit of 2 x 10
6
 cells in 200μl PBS 
of each cell-line was injected into a single subcutaneous site in the right shoulder of 8 week-old male 
Nu/nu mice (Harlan Ltd., Oxon, UK). Four groups of cells were assessed: PC3-Mcontrol, PC3-Mscramble, 
si-PRKC-ζ-b-PC3-MT1-6 and si-PRKC-ζ-b-PC3-MT1-3. Tumor growth was monitored twice-weekly and 
the volume calculated 
84
. When any tumor reached the maximum size allowed under the conditions of 
the Home Office Project Licence PPL 40/2270, all mice were sacrificed. Each animal was autopsied. 
All tissues were processed, embedded in paraffin wax and histological sections cut at 4µm before 
staining with Gill’s hematoxylin. All animal experiments were conducted under UKCCR guidelines. 
 
Hsp-27 expression and phosphorylation status 
Differential phosphorylation of regulatory protein Hsp-27 at Ser
15
, Ser
78
 and Ser
82
 was assessed by 
Western blotting the proteins extracted from ~1 x 10
7
 cells from each line. Cell pellets were suspended 
in 1 ml of CelLytic-M lysis buffer (Sigma C2978) containing 10μl protease inhibitor cocktail (Sigma 
P8340), 10μl PMSF (0.1mg/ml), Na3VO4 (1mM) and NaF (1mM). Protein concentrations were 
determined by Bradford assay (BioRad kit 500-0006). Aliquots containing ~10μg cell lysate proteins 
were separated electrophoretically in 12.5% (w/v) polyacrylamide Protogel quick-cast separating gels 
(National Diagnostics, EC-895). After separation, proteins were transferred onto PVDF membranes 
(GE Healthcare, RPN303F), blocked with a suspension of powdered dried milk in PBS (100mM, pH 
7.6) and incubated overnight with monoclonal antibodies to generic Hsp-27 or to each of the 
phosphorylated serine sites (Upstate Cell Signaling Solutions 06-478, 07-388, 04-447 and 04-448, 
respectively). After washing and incubation with HRP-labeled secondary antibodies, membranes were 
incubated in ECL-Plus reagent (GE Healthcare, RPN 2133) before exposure to Amersham Hyperfilm 
(GE Healthcare, 28906839). 
 
Glycoconjugate expression 
To determine whether PRKC-ζ knockdown affected oligosaccharide profiles, lectin binding was 
performed using intact cells and their protein extracts. Cell blocks were prepared from cell-lines PNT-2, 
PC3-Mcontrol, PC3-Mscramble, si-PRKC-ζ-b-PC3-MT1-6 
85
. Sections cut at 5 μm were stained for 
Neu5Acα2→3Gal- and Neu5Acα2→6Gal- using the biotinylated lectins (Vector Laboratories, 
Peterborough, UK) from Sambucus nigra and Maackia amurensis respectively 
86
.  Negative controls 
included the absence of staining when the lectins were not included in the staining protocol and removal 
of sialic acids with subsequent abolition of staining following pre-treatment of the slides with 
neuraminidase 
87
 prior to incubation with either of these lectins. Lectin-binding was confirmed using 
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avidin-fluorochrome conjugates visualized with an Olympus BX61 fluorescent microscope and x100 
objective. To identify global changes in glycoprotein expression following siRNA knockdown of 
PRKC-ζ-b, Western blotting of cell lysates using each lectin was performed as described for the 
detection of Hsp-27 (above) with the exception that non-specific binding of protein to the PVDF 
membranes was blocked with BSA (1.5%, w/v) rather than milk. Before use, the optimal dilution of 
each lectin in PBS (100mM, pH 7.6) containing BSA (1.5%, w/v) was determined by titration against 
separated PC3-Mcontrol cell-lysates.  
 
Gene microarray and expression analysis 
The effect of suppressing PRKC-ζ-b by gene knockdown on whole genome expression profiles was 
investigated using two-color Agilent Human genome 44k microarrays. Each hybridization was a 
distinct biological replicate. The design incorporated five cell-lines treated as fixed biological factors: 
PNT-2, PC3-Mcontrol, PC3-Mscramble, PC3-Mpool and si-PRKC-ζ-b-PC3-MT1-6 (PRKC-ζ-b knockdown). The 
PC3-Mscramble cells were the common control comparator and so expression differences between these 
cells and the other cell-types were used as contrasts in the gene expression analysis. Hybridizations and 
data acquisition were performed according to the Agilent Human Genome Microarray 44K protocol. 
Spatial representations of the hybridisation signals were examined to ensure that there were no artefacts. 
The distribution of background and foreground signals and pre-normalisation MA plots were examined 
to measure the quality of the hybridisation. Low quality spots identified by the Agilent image 
processing software were not used in the subsequent analyses. Expression signal estimates were derived 
from the red (cy3) and green (cy5) Agilent Processed Signal data by normalizing using the LOESS 
algorithm and background correction using a fitted convolution of normal and exponential distributions 
88, 89
. An Aquantile normalisation between arrays was also performed. Expression analysis of log2 
transformed normalised data was performed in the R statistical programming language (R v 2.8.0) using 
the BioConductor framework 
90
.  Gene expression was modeled with a fixed effects linear model with a 
term representing residual dye-effects and four cell-line specific contrasts in which the gene expression 
values of the control PC3-Mscramble cell lines were subtracted from the expression values of the PNT-2, 
PC3-Mcontrol, PC3-Mpool and si-PRKC-ζ-b-PC3-MT1-6 cell lines. A channel-specific design matrix was 
constructed using the PC3-Mscramble cells as a common reference and this was incorporated into a linear 
model using BioConductor limma 
91
.  For each cell-line contrast, a moderated t-statistic was computed 
for each probe with the resulting p-values adjusted for multiple testing using Benjamini and Hochberg’s 
method to control the false discovery rate 
92
. Those sequences with an adjusted p-value < 0.05 were 
considered significantly differentially expressed between the two groups being compared. Gene 
ontology (GO) term enrichment analysis was performed separately with lists of significantly up- and 
down-regulated genes to find significant functional terms (FatiGO http://babelomics.bioinfo.cipf.es/). 
GO terms and KEGG networks that were significantly associated with the genes expressed 
differentially between si-PRKC-ζ-b-PC3-MT1-6 and PC3-Mcontrol cell lines were assessed using 
hypergeometric tests (p < 0.001) 
93
.  The list of genes expressed differentially between si-PRKC-ζ-b-
PC3-MT1-6 and PC3-Mcontrol cell lines was uploaded into the Ingenuity pathway analysis application 
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(Ingenuity® Systems, www.ingenuity.com). A score was computed for each network according to the 
fit of the original set of significant genes. This score reflects the negative logarithm of the p-value, 
which indicates the likelihood of the focus genes in a network being found together as a result of 
random chance. 
 
Microarray validation 
In addition to NFKB1A, TNFSR6, MMP3 and MMP10 
32
, gene profiles were validated in the si-PRKC-ζ-
b-PC3-MT1-6 cells using qPCR to confirm the expression of PLAT, HSPB1, CDKN2C and FOXA2 with 
respect to PC3-Mscramble cells, when normalized against human β-actin. 
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Figure Legends 
 
Figure 1 - Immunohistochemical expression of PKC-ζ in TMA cores of prostatic tissues. 
Location of the high magnification regions shown below each of the cores is indicated by a 
corresponding rectangular field. Stromal expression was not identified in any of the malignant tissues 
examined. No expression of PKC-ζ was identified in the nuclei although the amounts may be below the 
level of immunohistochemical detection. 
 
i., ii, iii.) Normal, hyperplastic and mildly dysplastic prostatic tissue in which neither luminal nor 
basal epithelial cells express PKC-ζ either within the cytoplasm or in the nuclei.  
iv.) Dysplastic intra-glandular epithelium of cribriforming type strongly expressing PKC-ζ 
within the cytoplasm. 
v.) Moderately-differentiated prostatic adenocarcinoma (Gleason 3+3) weakly expressing 
PKC-ζ in the majority of malignant cells.  
vi.) Prostatic adenocarcinoma of pseudoglandular morphology (Gleason 4+3) strongly 
expressing PKC-ζ throughout the cytoplasm of all malignant cells.  
vii.) Moderately-differentiated prostatic adenocarcinoma (Gleason 3+3) morphologically similar 
to that in v.) but negative for PKC-ζ expression. 
viii.) Poorly-differentiated prostatic adenocarcinoma (Gleason 5+5) strongly expressing PKC-ζ 
in the cytoplasm of the majority of the malignant cells. 
 
Magnification: All cores are magnified at x60. The detailed fields within each of the cores are 
magnified at x200. 
 
Figure 2 - Expression of PRKC-ζ-b in prostate cell-lines and following RNAi. 
PKC- ζ expression assessed between normal, hyperplasic, PIN and cancer cores. Information on PKC-ζ 
staining intensity was available for 2879 cores (783 patients). The figure presents the distribution of 
PKC-ζ staining intensity in the 901 normal cores, 798 hyperplasic cores, 38 PIN cores and 1142 cancer 
cores. (B) The maximum staining intensity in the1142 cancer cores was subsequently calculated for 
each patient. The distribution of this variable is shown in the histogram. (C) Clinical outcome of 
patients with respect to death from prostate cancer (p < 0.001) according to intensity of PKC-ζ 
expression (≤ 2 vs = 3). (D) Clinical outcome of patients with respect to death from all causes (p < 
0.002) according to intensity of PKC-ζ expression (≤ 2 vs = 3). 
 
Figure 3 
Expression of PRKC-ζ-b in prostate cell-lines and following RNAi: (A) Western blotting of control 
cell-lines confirming high expression of PKC-ζ in PC3-M cells and virtually undetectable levels in the 
non-malignant PNT-2 cell-line. Detection of β-actin protein was used as the standard. (B & C) Northern 
blot detection of PRKC-ζ-b mRNA in four prostate cell-lines following standard two-step RT-PCR. 
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Expression of β-actin was used as the reference gene. (D) Following stable knockdown of PRKC-ζ-b 
using vector-based si-RNA, altered cell morphologies were observed in the subsequent cell-clones. 
Comparison of the low power views of the parental (i) and si-PRKC-ζ-b-PC3-MT1-6 cells (ii) revealed 
significant loss of adhesion by the genetically modified cells. On high power, whereas the original (iii) 
cells were unicellular and compact, the transfected cells (iv) were disparate, non-adhesive and contained 
many multinucleate forms. (E) Using qPCR, reduced gene expression was identified in all nine cloned 
knockdown cell-lines when compared to the parental control cells. The data shown are the mean (± 
S.D.) of three separate experiments. The level of gene expression in the PNT-2 cells was set at unity.  
 
Figure 4 
Growth and migration of cells in-vitro: (A) Comparison of cell proliferation in monolayer cultures. 
PRKC-ζ-b gene knockdown reduced proliferation of the transfectant clones, particularly the si-PRKC-ζ-b-
PC3-MT1-6 cells. The effect of transfecting scrambled RNA was not statistically significant. (B) 
Apoptosis was marginally enhanced in the knockdown si-PRKC-ζ-b-PC3-MT1-6 cells when compared to 
the controls, transfected scramble RNA and to comparator clone si-PRKC-ζ-b-PC3-MT1-2 cells. (C & D) 
Down-regulation of PRKC-ζ-b gene expression impaired the ability of cells to form colonies in oft agar. 
Cells from clones T1-6 and T1-2, scramble control,PC3-M and PNT-2 controls were cultured 5 days.  
Measurements were taken each day. Significant differences were found between different cell clones 
with the most pronounced down-regulation of colony formation occurring in the si-PRKC-ζ-b-PC3-MT1-6 
cells. Quantitative assessment of tumorigenesis of different clones was determined by counting the 
number of colonies. The data shown are the mean (± S.D.) of three separate experiments. (E & F) 
RNAi-induced down-regulation of PRKC-ζ-b impaired the ability of PC3-M transfectant cells to migrate 
in a Matrigel invasion assay. After five days in culture, invasion probabilities in T1-6, T1-2 groups were 
calculated as the ratio of number of cells invading through the Matrigel insert membrane relative to the 
mean number of PC3-Mcontrol cells.  
 
Figure 5 
Growth of cells in-vivo: (A) Inoculation of 2x10
6
 cells was performed subcutaneously into the shoulder 
fat pad of each animal in 4 groups of 8 male immuno-compromised CD/1 nude mice. The groups 
comprised the transfectant clones si-PRKC-ζ-vb-PC3-MT1-6 and si-PRKC-ζ-vb-PC3-MT1-2, PC3-Mcontrol and 
PC3-Mscramble cells. Tumor size was measured every 3 days for 15 days after the inoculation. Tumor 
volumes were calculated using the formula V=L x H x W x 0.5237. The data are the mean tumor 
volumes (±S.D.) of eight animals in each group. (B & C) The histogram shows the occurrence and 
weight of tumor present in each animal on day 15 when all animals were sacrificed. When the data in 
each group were combined, the histogram shows the mean tumor volume (±S.D.) of the eight animals in 
each group. 
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Figure 6 
Effect of PRKC-ζ-b knockdown on Hsp-27 and glycoconjugate expression: (A) Western blotting of 
Hsp-27 protein and of phosphorylation-specific sites P-Ser15, P-Ser78 and P-Ser82 following si-RNA 
reduction of PRKC-ζ-b in the si-PRKC-ζ-b-PC3-MT1-6 cells did not affect expression of the generic 
protein, although this was reduced in comparable experiments to knock down genes FABP5 and RPL19. 
Conversely, phosphorylation of P-Ser82 was specifically enhanced when compared to the PC3 and 
PC3-Mcontrol cells and to the FABP5 and RPL19 knock-down cells. (B) Western blotting using 
Sambucus nigra and Maackia amurensis revealed differences in sialylated glycoproteins expressed by 
the si-RPKC-ζ-b-PC3-MT1-6 cells when compared to the PC3-Mcontrol and PC3-Mscramble cells 
confirming specificity of the role of the gene PRKC-ζ-b in modulating expression of the proteins, or the 
level of their sialylation, at 56kD and 49kD. (C) Control cell-line PC3-M and gene knockdown cell-line 
si-PRKC-ζ-b-PC3-MT1-6 expressed terminal fucose residues identified by Lotus and Aleuria lectins but 
not by Ulex. The later was not affected by removal of sialic acid residues using neuraminidase. Sialic 
acids linked 2→3Gal- and 2→6Gal- were identified using the lectins from Sambucus nigra and 
Maackia amurensis, respectively. These were differentially expressed by the control and knockdown 
cell-lines since staining by Maakia was abrogated by neuraminidase. However, no global difference in 
expression of these glycoconjugates was identified following PRKC-ζ-b knockdown. 
 
Figure 7 
Differential expression of genes following si-PRKCZ-ζ-b knockdown: Heat map of gene expression 
profiles from mRNA expressed by the top 50 up-regulated and top 50 down-regulated genes 
(Supplemental Tables 2 & 3) in the cloned prostate cell-line si-RPKC-ζ-b-PC3-MT1-6 when compared to 
non-malignant PNT-2 cells and to PC3-Mscramble cells. Hierarchical clustering is shown. Green 
indicates genes over-expressed and red indicates genes down-regulated in each sample when compared 
to scramble transfected cells.  
 
Figure 8 - Gene Ontology (GO) enrichment pathway analysis. 
Analysis of genes modulated following PRKCZ-ζ-b knockdown identified four pathways principally 
affected: (a. & b.) genes known to be regulated by NFKB and almost universally down-regulated (c.) 
(c.) gene networks linked to KDMSB, MCM6 and DDIT3 and (d.) This analysis revealed that some of 
the genes modulated by down-regulated expression of PRKC-ζ-b are interconnected, emphasizing the 
numerous pathways for cross-talk between apparently distinct biological processes. 
